GlassScriptPhysician profile
James L Lin
NPI 1770743502
$16,089.27
in general payments reported to CMS, 2019-2025
18 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $79.40 · 2021: $162 · 2023: $316 · 2024: $15K · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,365 · Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,262.50 |
| Travel and Lodging | $1,365.41 |
| Food and Beverage | $1,080.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Creo Medical INC. | $12,611.51 | 2024 | Speedboat Ultraslim (Sb1l) |
| Ethicon INC. | $1,262.50 | 2024 | |
| Boston Scientific Corporation | $1,202.52 | 2021-2024 | Axios, Coredx |
| Intuitive Surgical, INC. | $222.18 | 2023-2025 | Da Vinci Surgical System |
| Galvanize Therapeutics, INC | $198.47 | 2023 | Aliya System |
| Olympus America INC. | $147.35 | 2024 | Evis X1 Video System Center, Evis Exera III Colonovideoscope |
| Avanir Pharmaceuticals, INC. | $108.39 | 2019 | |
| Medtronic, INC. | $66.08 | 2025 | Endoflip |
| Novo Nordisk INC | $57.14 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $48.00 | 2025 | |
| Conmed Corporation | $30.16 | 2025 | Conmed Biliary |
| Daiichi Sankyo INC. | $24.32 | 2024 | Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.26 | 2020 | |
| Erbe USA INC | $20.52 | 2025 | Vio3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20.06 | 2019 | |
| Braintree Laboratories, INC. | $13.14 | 2021 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.